Wednesday, 04 February 2026

Vystar Enters Final Testing of Breakthrough Dialysis Water Filtration Technology

Vystar plans to apply Fluid Energy Conversion (FEC) technology to increase pathogen killing efficiency, reduce the size and cost of Vystar’s RxAir air purifiers

Vystar Corporation, a diversified innovation company with operations spanning eco-friendly products and collectables monetisation, announced that its water filtration enhancement device prototype is in the final stage of testing to improve dialysis efficiency for those affected by renal failure.

FEC is a global green energy entity whose patented and proprietary technologies harness sound energy in unique ways to destroy bacteria and viruses, improve water processing, and enhance chemical reactions. Vystar has acquired 100 per cent of the assets of Fluid Energy Conversion Inc., primarily consisting of its patent on the Hughes Reactor.

Dr Stone stated: “Severe droughts in the Western United States have placed a spotlight on the importance of a ready supply of clean water and the need to find new ways to reduce use, recycle and purify this precious resource. FEC’s patented technologies have the potential to be game-changing in both areas. FEC’s Hughes Reactor technology operates at the molecular level to convert the flow energy of water into ultrasound and cavitation energy, which are well known to enhance water treatment and purification.”

“Fluid Energy Conversion has multiple R&D initiatives relating to environmentally friendly product development and distribution that have the potential to revolutionise multiple industries and substantially improve our RxAir air purification systems, which we anticipate will catapult it to lead the competition,” stated Jamie Rotman, CEO of Vystar. “Vystar anticipates final testing of the water purification prototype in the current quarter for adapting Fluid Energy Conversion technology to enhance the effectiveness of the RxAir purification system to destroy airborne pathogens while decreasing the cost and size of Vystar’s RxAir units. The use of this patented technology is expected be a major differentiator of RxAir from the competition and is anticipated to be virtually impossible to emulate due to the patented IP.”

Rotman added, “In addition, Vystar intends to pursue completion of applications and product trials already underway for the FEC technology in multiple industries. We believe this has the potential to add new revenue streams and further diversify our product offering of eco-friendly solutions.”